A61L24/046

GEL COMPOSITIONS, SYSTEMS, AND METHODS

Methods of forming a gel and related methods of treating subjects with such gels are described. The method may include preparing a composition by combining a macromer comprising a first polyethylene glycol (PEG)-based polymer, a poly(ethylenimine)-based polymer, or a poly(1,2-glycerol) carbonate-based polymer, the macromer including at least one first functional moiety, a crosslinking agent comprising a second PEG-based polymer that includes at least one second functional moiety, and a photoinitiator, and activating the photoinitiator via a light source to form the gel.

GEL COMPOSITIONS, SYSTEMS, AND METHODS

Methods of forming a gel and related methods of treating subjects with such gels are described. The method may include preparing a composition by combining a macromer comprising a first polyethylene glycol (PEG)-based polymer, a poly(ethylenimine)-based polymer, or a poly(1,2-glycerol) carbonate-based polymer, the macromer including at least one first functional moiety, a crosslinking agent comprising a second PEG-based polymer that includes at least one second functional moiety, and a photoinitiator, and activating the photoinitiator via a light source to form the gel.

Anisotropic wound closure systems

Novel compositions and systems for closure of wounds are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is also directed to a novel platinum catalyst for use in such compositions. The catalyst provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.

ELASTOMERIC COMPOSITIONS AND THEIR APPLICATIONS
20180009951 · 2018-01-11 ·

A gel is provided which is the condensation reaction product of the following composition: (i) at least one condensation curable silyl terminated polymer having at least one hydrolysable and/or hydroxyl functional group(s) per molecule; (ii) a cross-linker selected from the group of a silicone, an organic polymer, a silane or a disilane molecule which contains at least two hydrolysable groups per molecule; and (iii) a condensation catalyst selected from the group of titanates, zirconates or tin (II). The molar ratio of hydroxyl and/or hydrolysable groups in polymer (i) to hydrolysable groups from component (ii) is between 0.5:1 and 1:1 using a monosilane cross-linker or 0.75:1 to 3:1 using disilanes, and the molar ratio of M-OR or tin (II) functions to the hydroxyl and/or hydrolysable group(s) in polymer (i) is comprised between 0.01:1 and 0.5:1, where M is titanium or zirconium. The composition, and uses for the gel are also disclosed.

Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

BIOCOMPATIBLE ADHESIVES AND METHODS OF MANUFACTURE THEREOF
20230001046 · 2023-01-05 ·

A biocompatible adhesive is provided comprising one or more water insoluble compounds of structure (1) wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4; or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

METHODS FOR PREPARING POLYMERIZED MATRIX WITH CONTROLLABLE THICKNESS
20230026886 · 2023-01-26 ·

The present disclosure relates in some aspects to methods for preparing a thin polymer matrix (e.g., a hydrogel matrix) having a biological sample embedded therein for in situ analysis of one or more analytes.

Method for manufacturing a wound dressing and a wound dressing

A method for manufacturing a wound dressing having a substrate, and a wound dressing manufactured by such a method are described. The method has a step of providing a sacrificial layer of material to be perforated by means of a hot pin perforator, in order to remove any molten residues on the heated pins of the hot pin perforator, before the same pins are used to make holes in the substrate. The presented method is cost effective, robust and reduces the risk of contaminating substances being embedded in the substrate during the hole making process.

Method for manufacturing a wound dressing and a wound dressing

A method for manufacturing a wound dressing having a substrate, and a wound dressing manufactured by such a method are described. The method has a step of providing a sacrificial layer of material to be perforated by means of a hot pin perforator, in order to remove any molten residues on the heated pins of the hot pin perforator, before the same pins are used to make holes in the substrate. The presented method is cost effective, robust and reduces the risk of contaminating substances being embedded in the substrate during the hole making process.

DEVICE AND METHOD OF CREATING A FLUID CONTAINMENT FIELD FOR ADMINISTERING THERAPEUTICS TO A NERVE
20230225733 · 2023-07-20 ·

A severed nerve may be surgically rejoined and severed axons fused via sequential administrations of solutions. The solutions may include a priming solution comprising methylene blue in a Ca.sup.2+-free saline solution, a fusion solution comprising about 50% (w/w) PEG, and a sealing solution comprising Ca.sup.2+-containing saline. The PEG fusion solution may be applied in a nerve treatment device configured to isolate the injured segment of the nerve. The device may include a containment chamber for creating a fluid containment field around the anastomosis. The device may have slits, slots, and/or apertures in opposing endwalls of the device designed to receive the nerve. The device may have an open bath configuration or may include separable lower and upper bodies to create a closed bath configuration. The device may include one or more fluid ports in fluid communication with the containment chamber for introducing and/or removing fluid.